



REC'D 0,1 JUL 2004

Rec'd 7/PTO 19 AUG 2004

PCT


WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)				
PCT 21044 International application No.	International filing date (day/mor	nth/year) Priority date (day/month/year)				
		01 March 2002 (01.03.2002)				
PCT/US03/05947 International Patent Classification (IPC)	27 February 2003 (27.02.2003) or national classification and IPC	07 1/1111011 2002 (07.100.12002)				
		1 - 548/141 144 248 251 253: 514/363, 364, 380, 381				
IPC(7): C07D 271/10, 285/12, 257/06, 261/06; A61K 31/42, 45 and US Cl.: 548/141, 144, 248, 251, 253; 514/363, 364, 380, 381 Applicant						
Applicant						
MERCK & CO., INC.						
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.						
2. This REPORT consists of a total of 3 sheets, including this cover sheet.						
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a total of sheets.						
3. This report contains indications relating to the following items:						
I Basis of the rep	port	·				
II Priority						
III Non-establishm	III Non-establishment of report with regard to novelty, inventive step and industrial applicability					
IV Lack of unity of	IV Lack of unity of invention					
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
VI Certain docum						
VII Certain defects	VII Certain defects in the international application					
VIII Certain observations on the international application						
Date of submission of the demand	Date	e of completion of this report				
12 September 2003 (12.09.2003)	09 J	une 2004 (09.06.2004)				
Name and mailing address of the IPEA/US		norited officer South was				
Mail Stop PCT, Attn: IPEA/US Commissioner for Patents		norized officer Sauhunch fer				
P.O. Box 1450 Alexandria, Virginia 22313-1450		ephone No. (571) 272-1600				
Facsimile No. (703) 305-3230 Form PCT/IPEA/409 (cover sheet)(July						





INTERNATIONAL PRELIMINARY EXAMINATION REPORT

PCT/US03/05947

I.	Basis of the report	
1.	With regard to the elements of the international application:*	
	the international application as originally filed.	1
	the description:	
	pages 1-75 as originally filed	ĺ
	pages NONE , filed with the demand	
	pages NONE , filed with the letter of	ı
	the claims:	
	ac ac ac ac originally filed	
	pages NONE as amended (together with any statement) under Article 19	l
	pages NONE filed with the demand	1
	pages NONE, filed with the letter of	1
	the drawings:	1
	pages NONE as originally filed	
	pages NONE, filed with the demand	ŀ
	pages NONE , filed with the letter of	l
	the sequence listing part of the description:	l
	pages NONE , as originally filed	
	nages NONE . filed with the delitatio	İ
	pages NONE filed with the letter of	ı
2	. With regard to the language, all the elements marked above were available or furnished to this Authority in the	١
ľ	torming in which the international application was filed, unless otherwise indicated under this item.	
	These elements were available or furnished to this Authority in the following language which is:	١
	the language of a translation furnished for the purposes of international search (under Rule23.1(b)).	١
	the language of publication of the international application (under Rule 48.3(b)).	1
	the language of the translation furnished for the purposes of international preliminary examination (under Rules	١
	55.2 and/or 55.3).	١
, ا	with regard to any pucleotide and/or amino acid sequence disclosed in the international application, the	١
١.	international preliminary examination was carried out on the basis of the sequence listing:	1
l	contained in the international application in printed form.	١
١	filed together with the international application in computer readable form.	١
١	furnished subsequently to this Authority in written form.	۱
	furnished subsequently to this Authority in computer readable form.	١
i	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the	١
١	international application as filed has been furnished.	١
1	micriational approaches as most and the computer readable form is identical to the written sequence listing	12
	The statement that the information recorded in computer readable form is identical to the written sequence listing	
1	has been furnished.	1
1	4. The amendments have resulted in the cancellation of:	ļ
١	the description, pages NONE	
١	the claims, Nos. NONE	
	the drawings, sheets/fig NONE	
Ì	5. This report has been established as if (some of) the amendments had not been made, since they have been considered to go	
	havend the disclosure as filed, as indicated in the Supplemental BOX (Kult 70.2(c)).	
	The state of the state of the receiving Office in response to an invitation under Afficie 14 are rejerred to	ιπ
1	Alia and an aminimally filed, and are not annexed to this think like an intermediation of the commentation	
Ì	** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.	
- 1		_





International application No. PCT/US03/05947

v.	Reasoned statement under Rule 66.2(a) citations and explanations supporting su	(ii) with regard to	novelty, inventive step or industrial applicability;
1.	STATEMENT		
	Novelty (N)	Claims 1-29 Claims NO	NO
	Inventive Step (IS)	Claims 1-29 Claims NO	NO
	Industrial Applicability (IA)	Claims <u>1-2</u> Claims <u>NO</u>	NO

2. CITATIONS AND EXPLANATIONS

The invention relates to aminoalkylphosphonates and related compounds, compositions and their methods of using such compositions that are useful for treating immune mediated diseases and conditions. Considering the prior art cited (US 5,830,869 and US 5,677,282) in the International search report, claims 1-29 of this invention is novel. The closest prior art of record is Mitchell et al (US 5,830,869). Claims 1-29 meet the criteria set out in PCT rticle 33(2)-(4), because the prior art do not teach or fairly suggest the pharmaceutical compositions comprising a compound which are useful for the treatment of immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection.

Form PCT/IPEA/409 (Box V) (July 1998)